Logo image of TLSI

TRISALUS LIFE SCIENCES INC (TLSI) Stock Fundamental Analysis

NASDAQ:TLSI - Nasdaq - US89680M1018 - Common Stock - Currency: USD

5.36  -0.3 (-5.3%)

Fundamental Rating

2

Overall TLSI gets a fundamental rating of 2 out of 10. We evaluated TLSI against 572 industry peers in the Biotechnology industry. TLSI may be in some trouble as it scores bad on both profitability and health. TLSI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLSI has reported negative net income.
TLSI had a negative operating cash flow in the past year.
TLSI Yearly Net Income VS EBIT VS OCF VS FCFTLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

The Return On Assets of TLSI (-264.48%) is worse than 91.78% of its industry peers.
Industry RankSector Rank
ROA -264.48%
ROE N/A
ROIC N/A
ROA(3y)-72.21%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSI Yearly ROA, ROE, ROICTLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 200 -200

1.3 Margins

With an excellent Gross Margin value of 86.69%, TLSI belongs to the best of the industry, outperforming 89.51% of the companies in the same industry.
TLSI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSI Yearly Profit, Operating, Gross MarginsTLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

TLSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLSI has more shares outstanding
The debt/assets ratio for TLSI has been reduced compared to a year ago.
TLSI Yearly Shares OutstandingTLSI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
TLSI Yearly Total Debt VS Total AssetsTLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

TLSI has an Altman-Z score of -16.39. This is a bad value and indicates that TLSI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.39, TLSI is doing worse than 83.39% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.39
ROIC/WACCN/A
WACC10.57%
TLSI Yearly LT Debt VS Equity VS FCFTLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

TLSI has a Current Ratio of 2.40. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.40, TLSI is doing worse than 71.15% of the companies in the same industry.
TLSI has a Quick Ratio of 2.00. This is a normal value and indicates that TLSI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of TLSI (2.00) is worse than 73.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.4
Quick Ratio 2
TLSI Yearly Current Assets VS Current LiabilitesTLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

TLSI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -211.20%.
Looking at the last year, TLSI shows a very strong growth in Revenue. The Revenue has grown by 240.11%.
EPS 1Y (TTM)-211.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.2%
Revenue 1Y (TTM)240.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.52%

3.2 Future

Based on estimates for the next years, TLSI will show a very strong growth in Earnings Per Share. The EPS will grow by 23.21% on average per year.
Based on estimates for the next years, TLSI will show a very strong growth in Revenue. The Revenue will grow by 45.07% on average per year.
EPS Next Y44.86%
EPS Next 2Y32.72%
EPS Next 3Y23.21%
EPS Next 5YN/A
Revenue Next Year60.46%
Revenue Next 2Y56.79%
Revenue Next 3Y54.53%
Revenue Next 5Y45.07%

3.3 Evolution

TLSI Yearly Revenue VS EstimatesTLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
TLSI Yearly EPS VS EstimatesTLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLSI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLSI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSI Price Earnings VS Forward Price EarningsTLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSI Per share dataTLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as TLSI's earnings are expected to grow with 23.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.72%
EPS Next 3Y23.21%

More info and screens

0

5. Dividend

5.1 Amount

TLSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRISALUS LIFE SCIENCES INC

NASDAQ:TLSI (3/7/2025, 8:00:01 PM)

5.36

-0.3 (-5.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)03-27 2025-03-27/bmo
Inst Owners11.7%
Inst Owner Change5.77%
Ins Owners21.45%
Ins Owner Change3.56%
Market Cap163.91M
Analysts82.86
Price Target11.67 (117.72%)
Short Float %0.93%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.13%
Min EPS beat(2)58.27%
Max EPS beat(2)66%
EPS beat(4)3
Avg EPS beat(4)3.03%
Min EPS beat(4)-121.65%
Max EPS beat(4)66%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.09%
Min Revenue beat(2)-2.55%
Max Revenue beat(2)4.72%
Revenue beat(4)3
Avg Revenue beat(4)1.87%
Min Revenue beat(4)-2.55%
Max Revenue beat(4)4.72%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.76%
PT rev (3m)-4.02%
EPS NQ rev (1m)-1.96%
EPS NQ rev (3m)-2.99%
EPS NY rev (1m)-0.2%
EPS NY rev (3m)4.36%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-1.46
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS1.09
BVpS-0.67
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.48%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.69%
FCFM N/A
ROA(3y)-72.21%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 88.58%
Cap/Sales 2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.4
Quick Ratio 2
Altman-Z -16.39
F-Score2
WACC10.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-211.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-82.2%
EPS Next Y44.86%
EPS Next 2Y32.72%
EPS Next 3Y23.21%
EPS Next 5YN/A
Revenue 1Y (TTM)240.11%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%41.52%
Revenue Next Year60.46%
Revenue Next 2Y56.79%
Revenue Next 3Y54.53%
Revenue Next 5Y45.07%
EBIT growth 1Y-69.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.44%
EBIT Next 3Y27.22%
EBIT Next 5Y20.44%
FCF growth 1Y-1976.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1945.81%
OCF growth 3YN/A
OCF growth 5YN/A